title: [A cross-sectional study on application of glucocorticoid in systemic lupus erythematosus patients].
abstract: Objective:To explore the status of glucocorticoid application in patients with systemic lupus erythematosus (SLE) in China.Methods:Epidemiological survey was used. The SLE patients who met the 1997 classification criteria of American College of Rheumatology were enrolled. The usage of glucocorticoid and related adverse reactions were recorded and analyzed.Results:A total of 400 SLE patients were enrolled, including 35 men and 365 women. The average age was (37.4±14.0) years old, and the average duration of disease was (6.7±5.8) years. There were 310 patients using glucocorticoid as maintenance. Sixty-one percent (n=244) patients started using medium dose (prednisone 30-<60 mg/d) as the initial treatment of glucocorticoid, which lasted for(37±11)days.The time of drug duration in patients with low dose prednisone (7.5-<30 mg/d)and high dose (60-100 mg/d) was(92±20)and(17±3)days respectively (P<0.05 between 3 groups). However, patients receiving different initial dosage were of no discrepancy in the maintenance therapy. During maintenance, even though 51.0% (n=158) patients were on prednisone 2.5-5 mg/d, the duration of drug use in >5-10 mg/d groupwas longer[(29.9±3.3) months]. Patients with involvement of internal organs had a higher tendency to use 60-100 mg/d prednisone or pulse-dose therapy in the initial treatment, nevertheless these two groups had no difference of maintenance dosage. Among all 400 patients, 62 patients withdrew glucocorticoid, including 17 patients with disease remission (4.3%), 44 by self-withdrawal and one with adverse reaction.Conclusion:In China, the medium dosage of glucocorticoid is the most common initial treatment in patients with SLE.Prednisone 2.5-5 mg/d was the most common choicefor maintenance therapy. Currently, the proportion of glucocorticoid withdrawal remains low in SLE patients achieving remission.
authors.affiliation: Department of Rheumatology & Immunology, Peking University People's Hospital, Beijing 100044, China.
authors.forename: L L
authors.initials: LL
authors.lastname: Xu
authors.forename: Q Y
authors.initials: QY
authors.lastname: Guo
authors.forename: X Y
authors.initials: XY
authors.lastname: Cai
authors.forename: Z Y
authors.initials: ZY
authors.lastname: Da
authors.forename: H Q
authors.initials: HQ
authors.lastname: Zhu
authors.forename: L Y
authors.initials: LY
authors.lastname: Zhang
authors.forename: Y
authors.initials: Y
authors.lastname: Su
mesh_terms: D000328:Adult; D002681:China; D003430:Cross-Sectional Studies; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D005938:Glucocorticoids; D011241:Prednisone
keywords: Glucocorticoids; Initial treatment; Lupus erythematosus, systemic; Maintenance treatment